Target $14
Friday, November 15, 2024
Moderna continues to be the most shorted among S&P 500
Moderna continues to be the most shorted among S&P 500 healthcare stocks in October.
Cassava Sciences stock up on Alzheimer’s update
Cassava Sciences (SAVA) stock gains as company completes Phase 3 trial for Alzheimer's candidate simufilam, to release topline data.
https://seekingalpha.com/news/4295466-cassava-sciences-stock-alzheimers-update
Avid Bioservices gains as holder opposes $12.50 a share takeover
Avid Bioservices (NASDAQ:CDMO) rose 1.6% as a holder said that it's opposed the planned $12.50 a share sale to GHO Capital Partners and Ampersand Capital Partners.
Punch & Associates, which has a 4.5% stake in Avid Biosciences (CDMO), said the acquisition "materially undervalues" the company and "is opportunistically timed to take advantage of trough valuations and a likely inflection in the fundamentals of the business," according to a letter sent to Avid's board on Thursday.
Punch, which has been an investor in Avid (CDMO) since September 2020, said it plans to vote against the sale.
On Wednesday, Avid holder Brock Pond Capital Partners also said it doesn't plan to vote for the transaction as it significantly undervalues CDMO, according to a statement on Wednesday.
Eyenovia misses endpoint in 3-year Phase 3 study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Company to discontinue study, review full data set, and evaluate next steps for the program
CERo OKd to Start Phase 1 Trial of Lead Compound in Acute Myelogenous Leukemia
CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).
https://finance.yahoo.com/news/cero-therapeutics-inc-receives-fda-134500755.html
Elon Musk expands lawsuit against OpenAI, blasts ‘ill-gotten gains’ with Microsoft
Billionaire entrepreneur Elon Musk expanded his lawsuit against ChatGPT maker OpenAI, adding federal antitrust and other claims and adding OpenAI’s largest financial backer Microsoft as a defendant.
Musk’s amended lawsuit, filed on Thursday night in federal court in Oakland, Calif., said Microsoft and OpenAI illegally sought to monopolize the market for generative artificial intelligence and sideline competitors.
Like Musk’s original August complaint, it accused OpenAI and its chief executive, Sam Altman, of violating contract provisions by putting profits ahead of the public good in the push to advance AI.
“Never before has a corporation gone from tax-exempt charity to a $157 billion for-profit, market-paralyzing gorgon — and in just eight years,” the complaint said. It seeks to void OpenAI’s license with Microsoft and force them to divest “ill-gotten” gains.
OpenAI in a statement said the latest lawsuit “is even more baseless and overreaching than the previous ones.” Microsoft declined to comment
“Microsoft’s anticompetitive practices have escalated,” Musk’s attorney Marc Toberoff said in a statement. “Sunlight is the best disinfectant.”
Musk has a long-simmering opposition to OpenAI, a startup he co-founded and that has since become the face of generative AI through billions of dollars in funding from Microsoft.
Musk has gained new prominence as a key force in President-elect Donald Trump’s incoming administration. Trump named Musk to a new role designed to cut government waste, after he donated millions of dollars to Trump’s Republican campaign.
The expanded lawsuit said OpenAI and Microsoft violated antitrust law by conditioning investment opportunities on agreements not to deal with the companies’ rivals. It said the companies’ exclusive licensing agreement amounted to a merger lacking regulatory approvals.
In a court filing last month, OpenAI accused Musk of pursuing the lawsuit as part of an “increasingly blusterous campaign to harass OpenAI for his own competitive advantage.”
Subscribe to:
Posts (Atom)